Virological and Immunological Determinants of Arbovirus Infection in New Caledonia

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, particularly in tropical and sub-tropical countries. In New Caledonia, dengue epidemics are recurrent and may be associated with the co-circulation of other arboviruses such as Zika or chikungunya. The virological determinants which condition the occurrence of these epidemics may be linked to an increased vectorial competence of the vector mosquito Aedes aegypti for a particular viral isolate. In fact, the Aedes aegypti mosquito is infected by making a blood meal on a person infected with an arbovirus. The virus infects its digestive tract, then spreads throughout the mosquito's body until it reaches its salivary glands. The virus is then present in the saliva and will be injected into the human host during a new blood meal. Some viral variants are best transmitted by Aedes aegypti. In general, the study of this vectorial competence is carried out by experiments in the laboratory during which an artificial blood meal composed of mammalian blood (human, rabbit, etc.) is mixed with a viral stock. Carrying out deported blood meals during which blood collected from patients infected with an arbovirus is used to gorge mosquitoes makes it possible to place oneself in experimental conditions as close as possible to the natural cycle of transmission of arboviruses. In the human host, cells of the myeloid lineage present in the peripheral blood constitute preferred targets of replication for arboviruses. At the same time, the peripheral blood cells of patients are activated in response to infection and secrete many soluble factors released into the blood of patients. The study of blood samples from patients infected with arboviruses is therefore of prime importance for understanding both the replicative mechanisms of arboviruses but also the immune response they induce.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No
View:

• Major patient

• Patient with clinical signs suggestive of an arbovirus infection:

• Fever And at least 2 clinical signs suggestive of arbovirus among which myalgia, retro-orbital pain, drop in platelets (if data available), digestive symptoms, etc.

• Appearance of clinical signs suggestive of an arbovirus infection in the 7 days preceding the blood sample.

• Patient informed of the performance of the research, the collection of data and biological samples

• Patient who has given their consent to participate in the research by authorizing the collection of data, the collection of an additional blood sample and the use of this sample

Locations
Other Locations
New Caledonia
Centre Hospitalier Territorial de Nouvelle-Calédonie
Recruiting
Dumbéa Sur Mer
Contact Information
Primary
Myrielle Dupont-Rouzeyrol, PhD
mdupont@pasteur.nc
+687 27 75 30
Backup
Catherine Inizan, PhD
cinizan@pasteur.fr
+687 27 26 66
Time Frame
Start Date: February 15, 2021
Estimated Completion Date: February 15, 2026
Participants
Target number of participants: 250
Treatments
Other: Patient infected by arboviruses
Related Therapeutic Areas
Sponsors
Collaborators: Centre Hospitalier Territorial de Nouvelle-Calédonie, Institut Pasteur de Nouvelle-Calédonie
Leads: Institut Pasteur

This content was sourced from clinicaltrials.gov

Similar Clinical Trials